Gastrointestinal perforation due to vasculitis at primary diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA) despite a high dose glucocorticosteroids treatment
© Assmann et al.; licensee Springer. 2014
Received: 25 February 2014
Accepted: 6 June 2014
Published: 4 August 2014
Eosinophilic granulomatosis with polyangiitis (EGPA) belongs to the systemic ANCA-associated vasculitides which may develop life-threatening major organ involvement, such as eosinophilic pulmonary infiltration, neuropathy, acute nephritis, myocarditis, and gastrointestinal (GI) tract involvement. Here, two cases of EGPA are presented developing perforation of the bowel at primary diagnosis after 7 respectively 10 days of initiation of high-dose glucocorticosteroides (GC) therapy.
Two male patients, aged 32 (case 1) and 36 years (case 2), were admitted to the hospital with the symptoms of dyspnea, fatigue, fever, and chest pain. The patients completed the previously published revised international Chapel Hill nomenclature of EGPA. The two patients (case 1 and 2) developed acute abdominal pain after 7 (case 1) and ten days (case 2) on GC treatment. Computed tomography followed by surgery detected acute perforation of the small intestine (middle part of jejunum, case 1) and colon transversum (case 2). The resected specimens disclosed bowel perforation with severe transmural inflammation, edema, hemorrhage and vasculitis typically of EGPA. On the first post-operative day, therapy with cyclophosphamide (according to the Austin protocol) with a dosage of 750 mg/qm every 3 weeks (for 8 cycles) was initiated with good response within three months of treatment.
The course of disease of the two presented EGPA patients suggest that very early initiation of intensified immunosuppressive treatment, preferentially with cyclophophomide or B cell depletion strategies, needs to be considered to avoid life-threatening complications of GI involvement.
Eosinophilic granulomatosis with polyangiitis (EGPA) belongs to the systemic vasculitides which may develop life-threatening major organ involvement Any type of vasculitis has the potential to cause local or diffuse pathological changes in the gastrointestinal (GI) tract based on the inflammation of vessel walls, followed by alterations of the blood flow and ischemic damage to the dependent organ (Çileda» et al. 2012; Singh et al. 2009; Venditti et al. 2011). Intestinal manifestations have to be considered more common in other vasculitis disease, such as polyarteriitis nodosa, however, it seems to occur as severe manifestation of EGPA (Nakamura et al. 2002). Several case reports have been published with EGPA and GI tract involvement. Venditti et al. have previously published a case of EGPA vasculopathy with large bowel perforation, however, the patient has been under long-term treatment of GC during his course of disease (Venditti et al. 2011). Two cases of EGPA have been presented with intestinal vasculitis, one of them with perforation as initial presentation of EGPA after 20 days of admission in the hospital (Venditti et al. 2011; Murakami et al. 2004). Varbanova et al. have presented a similar EGPA case to the cases, which here have been presented, showing vasculitic intestine perforation within 3 weeks after diagnosis of EGPA (Varbanova et al. 2011). Guellivin et al. have published data from a relatively large cohort of 96 patients: during the course of EGPA 30% of patients develop GI symptoms, such as abdominal pain, melena or hematemesis indicating intestinal vasulitic involvement (Guillevin et al. 1999). These data correspond to results from another cohort consisting in 150 EGPA patients previously published by (Moosig et al. 2013).
Here, two cases of EGPA are presented developing perforation of the bowel after initiation of high-dose GC therapy.
Patients and methods
The study was performed in compliance with the Helsinki Declaration, all patients have given the informed written consent to take part in the study, the agreement to perform the study was given by the Ethic Committee Saarland.
Eosinophilic granulomatosis with polyangiitis patients’ characteristics (case 1, 2)
Time of diagnosis
Dosage of prednisolone a
Days of GC treatment b
Manifestations of EGPA
Heart failure (NYHA stage)
Mononeuritis multiplex L1
Mild proteinuria (0.5 g/24 h)
Eosinophilic granulocytes d
The good response of treatment was documented in reduction of eoasinophilic granulocytes lower than 2000/μl, normalization of the lung spirometry, complete remission of the myocarditis (measeared with MRI), and normalization of kidney function (with normal urine sediment test). However, both of them showed not ameliorated but persistent neuropathy, and patient one suffered from a persistent reduced ejection fraction of the heart after 12 weeks. The p-ANCA levels have not changed during the treatment period in both cases.
We present two cases of GI perforation within two weeks after primary diagnosis of EGPA under treatment of high-dose GC. The macroscopic and histologic preparation of the involved intestinal tract proved unconstrained inflammation as the most probable cause of perforation. After immediate postoperative initiation of intravenous cyclophosphamide treatment both cases have shown clinical remission during the following 12 weeks.
The treatment of EGPA with GI vasculitic involvement at primary diagnosis may not be sufficiently treated by GC alone to protect from life-threatening and very early occuring complications such as GI perforation. Murakami et al. has published a similar case of primary diagnosis of EGPA with GI perforation 20 days after admission to hospital, however, the GC dosage was lower (Murakami et al. 2004).
In general, GI involvement seems to be an indicator of poor prognosis in this disease entity and has been reported in an estimated 20 – 50% of patients (Guillevin et al. 1996; Hayami et al. 2012; Bourgarit et al. 2005). However, larger, more informative clinical study cohorts of EGPA patients to evaluate the true prognostic impact of GI vasculitis are currently not available. Nevertheless, previously published data from the French Vasculitis Study Group have evaluated the “five factors score” (FFS) to predict the risk of death due to EGPA (Bourgarit et al. 2005); the FFS score is widely used to assess the EGPA prognosis by giving one point for the involvement of GI, one point for involvement of the heart and the central nervous system, respectively, and one or two for the kidney manifestation (depending on serum creatinine and proteinuria) (Pagnoux et al. 2007; Guillevin et al. 2011; Vaglio et al. 2012). In general, Moosig et al. has demonstrated the probable benefit of immunosuppressive treatment beyond GC in all stages of EGPA patients out of the Northern German vasculitis centre cohort (Moosig et al. 2013); in detail, with an initial FFS (score) of one or higher, the intravenous bolus application of cyclophosphamide has been documented as the most frequent treatment regime (71%).
In synopsis with the two cases we have presented here, there appears to be a rationale for an intensified immunosuppressive treatment approach beyond GC within the first week after EGPA diagnosis with GI involvement; conventional therapies such as cyclophosphasmide or previously establishing biological treatment modalities such as B cell depletion needs to be considered to avoid life-threatening GI manifestations with the goal to improve the outcome.
- Bourgarit A, Le Toumelin P, Pagnoux C, Cohen P, Mahr A, Le Guern V, Mouthon L, Guillevin L, French Vasculitis Study Group: Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore) 2005, 84(5):323-330. 10.1097/01.md.0000180793.80212.17View ArticleGoogle Scholar
- Çileda» A, Deniz H, Eleda» S, Özkal C, Düzgün N, Erekul S, Karnak D: An aggressive and lethal course of Churg-Strauss syndrome with alveolar hemorrhage, intestinal perforation, cardiac failure and peripheral neuropathy. Rheumatol Int 2012, 32(2):451-455.View ArticleGoogle Scholar
- Guillevin L, Lhote F, Gayraud M, Cohen P, Jarrousse B, Lortholary O, Thibult N, Casassus P: Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome: a prospective study in 342 patients. Medicine (Baltimore) 1996, 75(1):17-28.View ArticleGoogle Scholar
- Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P: Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999, 78(1):26-37.View ArticleGoogle Scholar
- Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Le Toumelin P, French Vasculitis Study Group (FVSG): The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 2011, 90(1):19-27.View ArticleGoogle Scholar
- Hayami C, Ishiguro N, Fukuya Y, Tokura Y, Kawashima M: Churg-Strauss syndrome presenting with severe cutaneous and intestinal ulcers. Eur J Dermatol 2012, 22(3):397-399.Google Scholar
- Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CG, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DG, Specks U, Stone JH, Takahashi K, Watts RA: 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013, 65(1):1-11.View ArticleGoogle Scholar
- Moosig F, Bremer JP, Hellmich B, Holle JU, Holl-Ulrich K, Laudien M, Matthis C, Metzler C, Nölle B, Richardt G, Gross WL: A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis 2013, 72(6):1011-1017.View ArticleGoogle Scholar
- Murakami S, Misumi M, Sakata H, Hirayama R, Kubojima Y, Nomura K, Ban S: Churg-Strauss syndrome manifesting as perforation of the small intestine: report of a case. Surg Today 2004, 34(9):788-792.View ArticleGoogle Scholar
- Nakamura Y, Sakurai Y, Matsubara T, Nagai T, Fukaya S, Imazu H, Hasegawa S, Ochiai M, Funabiki T, Mizoguchi Y, Kuroda M: Multiple perforated ulcers of the small intestine associated with allergic granulomatous angiitis: report of a case. Surg Today 2002, 32(6):541-546.View ArticleGoogle Scholar
- Pagnoux C, Guilpain P, Guillevin L: Churg-Strauss syndrome. Curr Opin Rheumatol 2007, 19(1):25-32.View ArticleGoogle Scholar
- Singh R, Singh D, Abdou N: Churg-Strauss syndrome presenting as acute abdomen: are gastrointestinal manifestations an indicator of poor prognosis? Int J Rheum Dis 2009, 12(2):161-165.View ArticleGoogle Scholar
- Vaglio A, Moosig F, Zwerina J: Churg-Strauss syndrome: update on pathophysiology and treatment. Curr Opin Rheumatol 2012, 24(1):24-30.View ArticleGoogle Scholar
- Varbanova M, Schütte K, Kuester D, Bellutti M, Franke I, Steinbach J, Scheidbach H, Malfertheiner P: Acute abdomen in a patient with ANCA-associated vasculitis. Dtsch Med Wochenschr 2011, 136(36):1783-1787.View ArticleGoogle Scholar
- Venditti D, Valerio B, Ielpo B, Buonomo O, Petrella G: Bowel perforations in a patient affected by Churg-Strauss syndrome under high-dose steroid treatment: will alternative drugs reduce risk of surgery? Rheumatol Int 2011, 31(9):1239-1241.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.